Treatment Pipeline Overview

Treatment Pipeline Overview

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Treatment Pipeline Overview</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Remternetug</td>
<td>Anti-Aβ mAb</td>
</tr>
<tr>
<td class="label">Levemelatonin</td>
<td>MT1/MT2 agonist</td>
</tr>
<tr>
<td class="label">Atacicept</td>
<td>TACI-Fc</td>
</tr>
<tr>
<td class="label">Semaglintide</td>
<td>GLP-1RA</td>
</tr>
<tr>
<td class="label">Blarcamesine</td>
<td>σ1 agonist</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">Amyloid targeting</td>
<td>12</td>
</tr>
<tr>
<td class="label">Tau targeting</td>
<td>15</td>
</tr>
<tr>
<td class="label">α-synuclein</td>
<td>8</td>
</tr>
<tr>
<td class="label">Neuroinflammation</td>
<td>20</td>
</tr>
<tr>
<td class="label">Neuroprotection</td>
<td>25</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>15</td>
</tr>
<tr>
<td class="label">Mitochondrial</td>
<td>12</td>
</tr>
<tr>
<td class="label">Synaptic</td>
<td>8</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Patients</td>
</tr>
<tr>
<td class="label">Phase 1</td>
<td>20-100</td>
</tr>
<tr>
<td class="label">Phase 2</td>
<td>100-300</td>
</tr>
<tr>
<td class="label">Phase 3</td>
<td>1000-3000</td>
</tr>
<tr>
<td class="label

Treatment Pipeline Overview

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Treatment Pipeline Overview</th>
</tr>
<tr>
<td class="label">Drug</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Remternetug</td>
<td>Anti-Aβ mAb</td>
</tr>
<tr>
<td class="label">Levemelatonin</td>
<td>MT1/MT2 agonist</td>
</tr>
<tr>
<td class="label">Atacicept</td>
<td>TACI-Fc</td>
</tr>
<tr>
<td class="label">Semaglintide</td>
<td>GLP-1RA</td>
</tr>
<tr>
<td class="label">Blarcamesine</td>
<td>σ1 agonist</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">Amyloid targeting</td>
<td>12</td>
</tr>
<tr>
<td class="label">Tau targeting</td>
<td>15</td>
</tr>
<tr>
<td class="label">α-synuclein</td>
<td>8</td>
</tr>
<tr>
<td class="label">Neuroinflammation</td>
<td>20</td>
</tr>
<tr>
<td class="label">Neuroprotection</td>
<td>25</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>15</td>
</tr>
<tr>
<td class="label">Mitochondrial</td>
<td>12</td>
</tr>
<tr>
<td class="label">Synaptic</td>
<td>8</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Patients</td>
</tr>
<tr>
<td class="label">Phase 1</td>
<td>20-100</td>
</tr>
<tr>
<td class="label">Phase 2</td>
<td>100-300</td>
</tr>
<tr>
<td class="label">Phase 3</td>
<td>1000-3000</td>
</tr>
<tr>
<td class="label">Phase 4</td>
<td>Post-approval</td>
</tr>
</table>

NeuroWiki contains 531 treatment entries covering drugs, biologics, gene therapies, and device-based interventions across all stages of development for neurodegenerative diseases. This comprehensive pipeline reflects decades of research investment and represents the most robust drug development effort in the field of neurology. The pipeline spans multiple disease categories including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), frontotemporal dementia (FTD), and rare tauopathies such as progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS)[@cummings2024].

The current pipeline demonstrates a significant shift from symptomatic treatments toward disease-modifying therapies targeting the underlying pathological mechanisms of neurodegeneration. This transition has been enabled by advances in biomarker development, improved understanding of disease biology, and innovative clinical trial designs that allow for earlier intervention and more precise patient selection[@park2024].

Alzheimer's Disease Pipeline

Approved Therapies

The landscape of approved Alzheimer's disease therapies has evolved dramatically since 2021, with three disease-modifying treatments now available:

[Aducanumab](/therapeutics/aducanumab) (Aduhelm) — Anti-Aβ monoclonal antibody received accelerated approval from the FDA in 2021, representing the first disease-modifying therapy targeting amyloid-beta. The approval was controversial due to conflicting Phase 3 trial results (EMERGE showed cognitive benefit while ENGAGE did not), and the drug was eventually discontinued in 2024. The development program provided valuable lessons about amyloid targeting and dose selection that have informed subsequent programs.

[Lecanemab](/therapeutics/lecanemab) (Leqembi) — Anti-Aβ monoclonal antibody received full FDA approval in 2023 following positive Phase 3 Clarity AD trial results showing 27% slowing of cognitive decline over 18 months. Lecanemab targets protofibrils, the most toxic form of soluble Aβ aggregates, and has demonstrated robust amyloid reduction on PET imaging. The approval represented a watershed moment for AD therapeutics, validating the amyloid hypothesis and establishing a new treatment paradigm[@cummings2024].

[Donanemab](/therapeutics/donanemab) — Anti-Aβ monoclonal antibody received FDA approval in 2024 based on the TRAILBLAZER-ALZ 2 trial showing significant slowing of cognitive decline in patients with early-stage AD. Donanemab targets amyloid plaques with high specificity and demonstrated the importance of amyloid clearance as a therapeutic endpoint.

Symptomatic treatments continue to play an important role in AD management:

• [Donepezil](/therapeutics/donepezil) — Cholinesterase inhibitor for mild to moderate AD
• [Rivastigmine](/therapeutics/rivastigmine) — Cholinesterase inhibitor available in oral and transdermal formulations
• [Memantine](/therapeutics/memantine) — NMDA receptor antagonist for moderate to severe AD
• Galantamine — Cholinesterase inhibitor with additional allosteric modulation properties

Phase 3 Programs

The AD Phase 3 pipeline represents the most robust in neurodegenerative disease drug development, with multiple mechanisms in late-stage development:

Remternetug represents a next-generation anti-amyloid antibody with potentially improved brain penetration and faster amyloid clearance. The ongoing Phase 3 program is evaluating both cognitive and biomarker outcomes in patients with early AD[@cummings2024].

Semaglintide (GLP-1 receptor agonist) represents the growing interest in metabolic approaches to AD. GLP-1 agonists have demonstrated neuroprotective properties in preclinical models through anti-inflammatory, anti-apoptotic, and mitochondrial protective mechanisms. The large-scale EVOKE and EVOKE+ trials will test whether these effects translate to human cognitive benefit[@cummings2024].

Atacicept targets the TACI receptor involved in B-cell activation and antibody production. Given the emerging role of humoral immunity in AD pathogenesis, this represents a novel immunomodulatory approach to disease modification.

Phase 2 Programs

The AD Phase 2 pipeline is diverse, spanning multiple mechanism categories:

Anti-tau therapies represent the second major pillar of AD-modifying treatment:

• Libraries of anti-tau antibodies targeting different tau conformations and post-translational modifications
• Tau aggregation inhibitors (e.g., LMTX, GV-971) targeting oligomer formation
• Tau kinase inhibitors targeting enzymes responsible for pathological phosphorylation

• BDNF mimetics to support synaptic function
• AMPA receptor modulators to enhance excitatory signaling
• Dendritic spine stabilizers to maintain synaptic architecture

• TREM2 agonists to enhance microglial phagocytosis of amyloid
• CSF1R inhibitors to modulate microglial proliferation
• NLRP3 inhibitors to block inflammasome activation

• Gene therapies using AAV vectors to deliver neurotrophic factors
• Cell therapies including stem cell approaches
• Device-based interventions such as focused ultrasound for amyloid clearance

Parkinson's Disease Pipeline

Approved Therapies

The PD treatment landscape includes both motor and non-motor symptom management:

Motor symptom treatments:

• [Levodopa/Carbidopa](/therapeutics/levodopa) — Gold standard dopamine precursor, available in immediate and extended-release formulations
• [Pramipexole](/therapeutics/pramipexole) — Dopamine agonist with high D3 receptor selectivity
• [Ropinirole](/therapeutics/ropinirole) — Non-ergot dopamine agonist
• [Rotigotine](/therapeutics/rotigotine) — Transdermal dopamine agonist
• [Rasagiline](/therapeutics/rasagiline) — MAO-B irreversible inhibitor
• [Selegiline](/therapeutics/selegiline) — MAO-B inhibitor (also available as transdermal patch)
• [Entacapone](/therapeutics/entacapone) — COMT inhibitor enhancing levodopa bioavailability

• [Deep Brain Stimulation](/therapeutics/deep-brain-stimulation) — Established surgical treatment for advanced PD
• Duodopa/Duopa — Levodopa-carbidopa intestinal gel for advanced disease
• Focused ultrasound — Emerging lesioning technique for tremor-dominant PD

Phase 3 Programs

The PD Phase 3 pipeline focuses on disease modification and symptomatic improvement:

[Gene therapies](/therapeutics/gene-therapy-pd) represent the most advanced disease-modifying approach:

• AAV-GAD (Prosavin) — Delivers glutamic acid decarboxylase to subthalamic nucleus
• AAV-AADC (VY-AADC01) — Delivers aromatic L-amino acid decarboxylase to putamen
• AAV-NTN (CERE-120) — Delivers neurturin to enhance dopaminergic function

• Prasinezumab (PRX002) — Anti-α-synuclein monoclonal antibody
• Cinpanemab (BIIB054) — Anti-α-synuclein antibody
• PD01A/PD03A — Synuclein-targeting vaccines

• DNL151 (BIIB122) — LRRK2 kinase inhibitor in Phase 3 (LUMINOSITY, LIGHTHOUSE)
• DNL151 — Showing promise in reducing LRRK2 activity in peripheral cells

• Ambroxol — Linding chaperone increasing glucocerebrosidase activity
• Venglustat (GZ161) — Substrate reduction therapy

Phase 2 Programs

The PD Phase 2 pipeline is extensive and diverse:

Neuroprotective agents:

• Inosine — Raising urate levels as antioxidant strategy
• CoQ10 — Mitochondrial electron transport chain cofactor
• Creatine — Energy buffer supporting mitochondrial function

• LRRK2 inhibitors — Multiple compounds in development
• PINK1/Parkin activators — Supporting mitophagy
• Alpha-synuclein aggregation inhibitors — Reducing toxic oligomers
• Glial modulation — Targeting astrocyte and microglial function
• [Regulatory T-Cell (Treg) Therapy](/therapeutics/treg-regulatory-t-cell-therapy-parkinsons) — Immunomodulation

Amyotrophic Lateral Sclerosis Pipeline

Approved Therapies

ALS treatment has evolved significantly in recent years with multiple FDA-approved disease-modifying options:

[Riluzole](/therapeutics/riluzole) — The first disease-modifying therapy for ALS (1995), reduces glutamate excitotoxicity through multiple mechanisms. Provides modest survival benefit (2-3 months) and remains standard of care.

[Edaravone](/therapeutics/edaravone) (Radicava) — Antioxidant therapy approved in 2017 based on Phase 3 trial showing reduced functional decline. Represents the first new ALS drug in over 20 years and validates neuroprotective approaches.

[Tofersen](/therapeutics/tofersen) (Qalsody) — Antisense oligonucleotide targeting SOD1 mutations, approved in 2023 for ALS patients with SOD1 mutations. First genetic therapy for ALS and demonstrates the potential for precision medicine approaches.

[Relyvrio](/therapeutics/relyvrio) (AMX0035) — Combination of sodium phenylbutyrate and taurursodiol, approved in 2022 based on Phase 2/3 trial showing survival benefit. Targets both mitochondrial dysfunction and oxidative stress.

Phase 3 Programs

The ALS Phase 3 pipeline addresses both genetic and sporadic forms of the disease:

Antisense oligonucleotides for genetic targets:

• WVE-004 — Targeting C9orf72 hexanucleotide repeat expansion (Phase 3 CHIMERA trial)
• BIIB278 — Additional C9orf72-targeting ASO
• ASO for FUS mutations — Expanding genetic precision medicine

• NurOwn (MSC-NTF) — Autologous mesenchymal stem cells engineered to secrete neurotrophic factors
• BrainStorm cell therapy — Phase 3 trial completed

• Treg cell therapy — Regulatory T-cell modulation
• Gene therapy approaches — AAV-mediated neurotrophic factor delivery
• Combination approaches — Multi-target strategies

Phase 2 Programs

The ALS Phase 2 pipeline includes innovative mechanisms:

• CNM-Au8 — Gold nanocrystal catalyzer addressing energy dysfunction
• Pridopidine — Dopamine D2 receptor modulator
• Masitinib — Tyrosine kinase inhibitor targeting microglia
• Anti-IL-6 therapies — Addressing neuroinflammation

Rare Disease Pipeline

PSP and CBD

The tauopathy pipeline has expanded significantly:

Anti-tau antibodies:

• Tilavonemab (ABBV-8E12) — Anti-tau antibody in Phase 2/3
• Zagotenemab (LY3303560) — Tau antibody targeting conformational epitopes
• Semorinemab — Anti-tau antibody showing mixed results in Phase 2

• LMTM — Tau aggregation inhibitor in Phase 3
• Masitinib — Kinase inhibitor with tau modulation properties

• Nimodipine — L-type calcium channel blocker
• Lithium — GSK-3β inhibitor

Huntington's Disease

The HD pipeline has evolved following the tominersen setback:

Antisense approaches:

• Tominersen (ASO-HTT) — Phase 3 program discontinued but data informing next-generation approaches
• IONIS-HTTRx (RG6042) — Antisense targeting HTT mRNA

• CRISPR-based therapies — Multiple programs in preclinical development
• AAV-delivered RNAi — Targeting mutant huntingtin

• Pridopazine — Dopamine stabilizer
• BDNF delivery — Gene therapy approaches
• Mitochondrial protectants — Multiple compounds

Pipeline by Mechanism

Analysis of the current pipeline reveals therapeutic priorities across mechanisms:

The dominance of amyloid and tau targeting in AD reflects the established understanding of AD pathogenesis and the large patient populations enabling clinical trials. Neuroinflammation targeting shows significant growth across all diseases, reflecting the recognition that immune dysfunction is a common pathological feature.

Gene therapy represents a growing segment of the pipeline, with multiple programs reaching late-stage development across AD, PD, and ALS. Advances in AAV delivery, promoter design, and manufacturing have enabled this expansion.

Regulatory Landscape

Recent Approvals (2023-2025)

The regulatory environment has become increasingly supportive of neurodegenerative disease therapeutics:

• Leqembi (lecanemab) — Full FDA approval 2023, first traditional approval of an AD disease-modifying therapy
• Donanemab — FDA approval 2024
• Qalsody (tofersen) — FDA approval 2023, first precision medicine for genetic ALS
• Relyvrio (AMX0035) — FDA approval 2022

Breakthrough Designations

The FDA has granted breakthrough therapy designation to over 40 therapies in the neurodegenerative space, enabling:

• More frequent regulatory interaction
• Rolling review applications
• Accelerated approval pathways
• Enhanced post-marketing requirements flexibility

Accelerated Approval Pathway

The accelerated approval pathway has become increasingly important:

• Amyloid PET as surrogate endpoint — Established for AD
• CSF biomarkers — Emerging as endpoints in other diseases
• Motor symptoms as endpoints — Established in PD

Clinical Trial Phases

Understanding the clinical development pathway is essential:

Neurodegeneration trials face unique challenges including long disease duration, need for biomarkers, patient heterogeneity, and significant placebo responses.

Challenges and Solutions

Trial Design Challenges

Long disease duration requires:

• Enriched enrollment criteria focusing on early-stage patients
• Use of biomarker endpoints enabling shorter trials
• Adaptive designs allowing sample size re-estimation

• Genetic stratification (e.g., LRRK2, GBA, SOD1, C9orf72)
• Biomarker-based subtyping
• Precision medicine approaches

• PET imaging for amyloid and tau
• CSF biomarkers (Aβ42, tau, p-tau, NfL, α-syn)
• Blood-based biomarkers (p-tau, NfL)
• Digital biomarkers (motor, cognitive)

Regulatory Solutions

Adaptive pathways are increasingly employed:

• Master protocols enabling multiple arms
• Platform trials for efficient screening
• Real-world evidence integration

• Patient-reported outcome measures
• Caregiver burden assessments
• Quality of life endpoints

Future Directions

Emerging Modalities

The pipeline is expanding beyond traditional small molecules:

• RNA therapeutics — ASOs, siRNA, miRNA approaches
• Cell therapies — Stem cell, iPSC-derived neurons
• Gene editing — CRISPR, base editing, prime editing
• Protein degraders — PROTACs, molecular glues
• Antisense — Multiple mechanisms in development

Combination Approaches

Recognition that neurodegeneration involves multiple pathways is driving:

• Multi-target small molecules
• Combination of disease-modifying and symptomatic treatments
• Rational polytherapy based on mechanism synergy

Prevention and Early Intervention

Growing focus on at-risk populations:

• Pre-symptomatic trials in genetic carriers
• Primary prevention studies
• Population-based screening programs

Pipeline by Disease

Alzheimer's Disease (AD)

Disease-modifying:

• [Lecanemab](/entities/lecanemab) (approved) — Anti-amyloid mAb
• Donanemab (approved) — Anti-amyloid mAb
• Remternetug (Phase 3) — Anti-amyloid mAb
• Semaglintide (Phase 3) — GLP-1RA

• [Aducanumab](/therapeutics/aducanumab) (withdrawn) — Anti-amyloid mAb
• [Cholinesterase inhibitors](/entities/cholinesterase-inhibitors) (approved) — Symptomatic
• [Memantine](/therapeutics/memantine) (approved) — Symptomatic

• [TREM2](/proteins/trem2) agonists — Microglial modulation
• Tau vaccines — Active immunization
• Synaptic protectors — Preserving connectivity

Parkinson's Disease (PD)

Disease-modifying:

• Inosine (Phase 3) — Urate elevation
• AAV-GAD (Phase 2) — Gene therapy
• LRRK2 inhibitors (Phase 3) — Kinase inhibition
• GBA modulators (Phase 2) — Chaperone therapy
• Treg therapy (Phase 1) — Immunomodulation

• Levodopa/carbidopa (approved) — Dopamine replacement
• Dopamine agonists (approved) — Receptor activation
• MAO-B inhibitors (approved) — Dopamine preservation

• Prazosin (approved) — Tremor management
• [Rivastigmine](/entities/rivastigmine) (approved) — Dementia

Amyotrophic Lateral Sclerosis (ALS)

Approved:

• Riluzole (approved) — Glutamate modulation
• Edaravone (approved) — Antioxidant
• Tofersen (approved) — SOD1 ASO (genetic)
• Relyvrio (approved) — Mitochondrial protection

• NurOwn (Phase 3) — Cell therapy
• C9orf72 ASOs (Phase 3) — Genetic therapy
• Pridopidine (Phase 3) — Neuroprotection

Related Pages

• [Treatment Efficacy Rankings](/treatment-efficacy-rankings)
• [Drug Target Landscape](/drug-target-landscape)
• [Protein Drug Targets](/proteins/protein-drug-targets)
• [Therapeutic Targetability Rankings](/mechanisms/therapeutic-targetability-rankings)
• [Alzheimer's Disease](/diseases/alzheimers-disease) — Disease overview
• [Parkinson's Disease](/diseases/parkinsons-disease) — Disease overview
• [ALS](/diseases/amyotrophic-lateral-sclerosis) — Disease overview

See Also

• [Aducanumab](/therapeutics/aducanumab)
• [Lecanemab](/therapeutics/lecanemab)
• [Donanemab](/therapeutics/donanemab)
• [Donepezil](/therapeutics/donepezil)
• [Memantine](/therapeutics/memantine)
• [Levemelatonin](/therapeutics/levemelatonin)
• [Atacicept](/therapeutics/atacicept)
• [Semaglintide](/therapeutics/semaglutide)
• [Levodopa/Carbidopa](/therapeutics/levodopa)
• [Pramipexole](/therapeutics/pramipexole)
• [Riluzole](/therapeutics/riluzole)
• [Edaravone](/therapeutics/edaravone)
• [Tofersen](/therapeutics/tofersen)

External Links

• [ClinicalTrials.gov - Neurodegeneration](https://clinicaltrials.gov/search?cond=Alzheimer+disease)
• [Alzheimer's Association Research](https://www.alz.org/)
• [Parkinson's Foundation Research](https://www.parkinson.org/)
• [ALS Association Research](https://www.als.org/)
• [FDA Drug Approvals](https://www.fda.gov/drugs)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: TREM2
• [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
• [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
• [Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: GLP1R, BDNF
• [TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: TREM2
• [Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — <span style="color:#ffd54f;font-weight:600">0.48</span> · Target: CHR2/BDNF
• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC

• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;
• [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson&#x27;s disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) &#x1f504;
• [Circuit-level neural dynamics in neurodegeneration](/analysis/SDA-2026-04-02-26abc5e5f9f2) &#x1f504;
• [Tau propagation mechanisms and therapeutic interception points](/analysis/SDA-2026-04-02-gap-tau-prop-20260402003221) &#x1f504;
• [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) &#x1f504;